ストックスクリーナーアプリを入手
1.77
1.72%
0.03
MAIA Biotechnology Inc (MAIA) 最新ニュース
MAIA Biotechnology partners with Roche for cancer treatment studies By Investing.com - Investing.com South Africa
Maia Biotechnology Signs Clinical Supply Deal With Roche; Shares Rise - MarketScreener
MAIA Biotech (MAIA) Partners with Roche for Cancer Treatment Study - GuruFocus
MAIA Biotechnology, Inc. Announces Master Clinical Supply Agreement with Roche for Hard-To-Treat Cancer Therapies - marketscreener.com
MAIA Biotechnology in pact with Roche for cancer treatments - Seeking Alpha
MAIA Biotechnology partners with Roche for cancer treatment studies - Investing.com
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies - BioSpace
MAIA Biotechnology Announces Agreement with Roche - TipRanks
MAIA Biotechnology Enters Inducement Offer Agreements - TipRanks
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Declines By 35.8% - Defense World
MAIA Biotechnology to Present at BIO International Convention 2025 - BioSpace
Jane Street Group LLC Makes New Investment in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) - Defense World
MAIA Biotechnology Reports Positive Phase 2 Trial Results - TipRanks
Why Is MAIA Biotechnology Stock Trading Higher On Thursday?MAIA Biotechnology (AMEX:MAIA) - Benzinga
MAIA Biotechnology's Promising Results in Lung Cancer Trial | MA - GuruFocus
MAIA Biotechnology's Promising Results in Lung Cancer Trial | MAIA Stock News - GuruFocus
MAIA Biotechnology Says New Responder In Non-Small Cell Lung Cancer Phase 2 Clinical Trial - marketscreener.com
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial - Business Wire
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer - BioSpace
MAIA Biotechnology Reports Promising Results from THIO-101 Phase 2 Trial | MAIA Stock News - GuruFocus
Maia Biotechnology Says Ateganosine Treatment Extends Median Overall Survival in Lung Cancer Study - marketscreener.com
Maia Biotechnology stock rises following positive trial results By Investing.com - Investing.com Nigeria
Maia Biotechnology stock rises following positive trial results - Investing.com Australia
MAIA Biotechnology Showcases Promising THIO-101 Trial Data - TipRanks
MAIA Biotechnology Announces Private Placement Agreement - TipRanks
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 4.1% Higher – Still a Buy? - Defense World
MAIA Biotechnology secures $669,500 in private placement By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces Private Placement of Approximately $669,500 - BioSpace
MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial - Yahoo
CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000 - BioSpace
MAIA Biotechnology secures $669,500 in private placement - Investing.com
MAIA Biotechnology doubles authorized shares - Investing.com Australia
MAIA Biotechnology doubles authorized shares By Investing.com - Investing.com South Africa
MAIA Biotechnology Increases Authorized Common Stock Shares - TipRanks
MAIA Biotechnology Approves Key Changes at Annual Meeting - TipRanks
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Business Wire
MAIA Biotechnology Announces Director Participation in Recent Private Placement - Business Wire
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
MAIA Biotechnology Raises $1.08M in Private Placement - TipRanks
MAIA Biotechnology launches $1.08M private placement - MSN
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire
MAIA Biotechnology secures $1.08 million in private placement By Investing.com - Investing.com Canada
Maia Biotechnology Announces $1.08 Million Private Placement - marketscreener.com
MAIA Biotechnology secures $1.08 million in private placement - Investing.com
MAIA Biotechnology Raises $1.08M at $1.50 Per Share to Advance Phase II Cancer Trial - Stock Titan
1.11%
1.70%
大文字化:
|
ボリューム (24 時間):